^
    15d
    Gencurix discloses clinical results of ‘liquid biopsy-based early diagnosis of colorectal cancer’ at ASCO (Gencurix Press Release)
    "Gencurix will disclose two colorectal cancer clinical research results using its self-developed molecular diagnostic test method at the 2024 American Society of Clinical Oncology (ASCO) annual conference held on May 31."
    Clinical data
    |
    COLO eDX • Droplex BRAF Mutation Test • Droplex KRAS Mutation Test
    1year
    Gencurix announces research results to expand the use of early cancer detection technology at AACR (Gencurix Press Release)
    "Gencurix...announced...that it had published a study showing that early colorectal cancer detection tests predicted colorectal cancer recurrence with 100% sensitivity prior to imaging tests...Gencurix utilized COLO eDX, an early detection test for colorectal cancer, to treat microscopic residual cancer after surgery..."
    Clinical data
    |
    COLO eDX
    1year
    Gencurix presented at AACR, a study on prognosis after colorectal cancer surgery (Gencurix Press Release)
    "Gencurix announced...that it will present the research results of 'Colloidex', an early detection test for colorectal cancer, at the American Association for Cancer Research (AACR)...Gencurix will present the results of a study on the correlation between micro-survival cancer (MRD) and recurrence after colorectal cancer surgery using Colloid X."
    Clinical data
    |
    COLO eDX
    1year
    Preliminary clinical validation of COLO eDX, a novel plasma circulating tumor DNA methylation assay for detecting colorectal cancer (AACR 2023)
    We have developed and validated the qualitative detection of methylation status of the bisulfite-converted target region in cfDNA. Further studies are warranted to evaluate the impact of COLO eDx on recurrence in a larger cohort of CRC patients.
    Clinical • Circulating tumor DNA • Epigenetic controller
    |
    COLO eDX